Eton Launches IMPAVIDO for Leishmaniasis, Expanding Rare Disease Portfolio
ETON has more than doubled off its 52-week low of $14.27.
Summary
Eton Pharmaceuticals announced U.S. commercial availability of IMPAVIDO (miltefosine) capsules, indicated for visceral, cutaneous, and mucosal leishmaniasis. The launch adds an eleventh commercial rare disease product to Eton's portfolio and includes the Eton Cares patient support program and a hospital consignment stocking initiative. This follows strong Q2 2026 results (revenue up 99% YoY) and recent licensing of ASN-001, reinforcing the company's rare disease expansion. The product relaunch leverages existing commercial infrastructure and could contribute incremental revenue, though the leishmaniasis market is niche. Watch for initial prescription uptake and any updates on hospital formulary access.
At the time of this announcement, ETON was trading at $57.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $14.27 to $66.37. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.